He has been a prolific inventor (72 issued U.S. patents), has published extensively and presented frequently at both national and international meetings, including the American Chemical Society and the Society for Biomaterials
BERKELEY, Calif. (PRWEB) May 28, 2008
Polymers specifically designed to degrade under physiological conditions are often referred to as "absorbable", "biodegradable" or "bioresorbable" polymers. With this in-licensing event, PTG will now be able to offer a wider range of new and generic bioresorbable polymers to the medtech industry for use in medical devices, drug delivery and tissue engineering.
"We are very happy to be working with Dr. Bezwada, who has more than 25 years of research experience in the medical device industry, including 20 years of service at Ethicon (Johnson & Johnson) prior to establishing Bezwada Biomedical in 2003," said Bob Ward, CEO of PTG. "He has been a prolific inventor (72 issued U.S. patents), has published extensively and presented frequently at both national and international meetings, including the American Chemical Society and the Society for Biomaterials," added Ward.
Ward and Dr. Bezwada will make a joint presentation—"A vertically integrated approach for tailoring bioresorbable polymers: from monomers to implantable devices"—at a "Corporate Lunch Forum" on Friday, May 30th, during the upcoming 8th World Biomaterials Congress (May 28-June 1) in Amsterdam.
ABOUT BEZWADA BIOMEDICAL
Bezwada Biomedical LLC is an innovation-based and technology-driven company focused on developing a range of novel, biocompatible and absorbable materials for use in next-generation medical devices and therapeutic applications. Since its inception in 2003, the company's mission has been to use the transforming power of chemistry to innovate and develop a range of biodegradable polymers that represent platform technologies capable of generating products to improve the health and quality of patients' lives.
Headquartered in Berkeley, Calif., The Polymer Technology Group, Inc. (PTG) specializes in the research, development, design, scale-up, and manufacture of new polymers, medical devices, and components. PTG's recently expanded operations to 70,000-square-feet comprise the equipment and expertise to support production-scale polymer synthesis through contract medical device manufacturing. On April 28th the company announced it has agreed to be acquired by DSM, the global Life Sciences and Materials Sciences company headquartered in the Netherlands. The union with PTG will enable DSM Biomedical to expand its unique portfolio of materials-based technologies which will benefit customers in the medical device and pharmaceutical industries. Closing of the acquisition is expected to take place by the end of May, 2008.